25 Mar 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Biolife Science's strategy of targeting the tumour-associated antigen HER-2/NEU has been the focus of a recent article in the peer-reviewed journal Breast Cancer Research and Treatment.
The article titled, 'Vaccination for the prevention and treatment of breast cancer - with special focus on Her-2/neu peptide vaccines', has been authored by Dr Ursula Wiedermann, Dr Adam B Davis and Dr Christoph C Zielinski.
The article concludes that among several delivery systems for the antigen the generation of peptide vaccines, such as Biolife's HER-Vaxx B cell peptide vaccine, is the simplest and most cost effective method.
The more complex DNA vaccines are the least developed for clinical application while widely tested T cell epitope vaccines present limitations mostly due to their human leukocyte antigen (HLA) restriction. These factors put B cell peptide vaccines at an advantage as they lack the HLA restriction and allow a broad use among cancer patients. Furthermore, in the case of HER-Vaxx, the clinical validity of the target (HER-2) has been extensively validated in human cancers.
Although the HER-Vaxx vaccine requires validation in phase II and Phase III trials, the first hurdle of effective B-cell immunity has been successfully achieved in a small cohort of women suffering with breast cancer. The article recommends therapeutic vaccines to be administered as early as possible once disease is detected so as to prevent the recurrence and dissemination of tumours.